Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Indeed gut tells me we get a overall market correction now that the big boys split. Took all $EVRI off the table this morning, getting some cash ready. GL
JohnCM
I took my profits.Am getting cash ready for a possible pullback in the markets. Just a gut feeling. Any profit is a good profit. (-:
Know who owns and what you own!
BioCryst Pharmaceuticals, Inc. is a company in the U.S. stock market and it is a holding in 37 U.S.-traded ETFs. BCRX has around 23.8M shares in the U.S. ETF market. The largest ETF holder of BCRX is the SPDR S&P Biotech ETF (XBI), with approximately 13.40M shares. Investors may also find of interest that the ETF with the largest allocation to BCRX stock is SPDR S&P Biotech ETF (XBI), with a portfolio weight of 1.07%. On average, U.S. ETFs allocate 0.14% of BCRX to their portfolios.
Additionally, BCRX is a favorite stock for Vanilla and Exchange-specific ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with BCRX as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 50.31%.
ETFs With BioCryst Pharmaceuticals, Inc.
https://www.etf.com/stock/BCRX
EVRI- Third party post on Yahoo message board today: I personally just got a training on the product this morning. now it depends how fast we deploy the software. hardware are all ready to go with our existing customers, which is about half of all the casinos in the US and majority of Canada. but of course it depend who buys it as well. but EVRI is looking good. they also bought out a promotional kisok system recent years, and it's doing quite well in a lot of casinos as well.
Everi Holdings Now On A Firm Recovery Path
https://seekingalpha.com/article/4371766-everi-holdings-now-on-firm-recovery-path
Looks like they changed the formulas structure likely better to fight the Covid.
https://pubchem.ncbi.nlm.nih.gov/compound/10445549
This stock has a long way to go more when 5-G is in full swing.
Set top boxes and portable, plus T-Mobile is the newest customer.
52-Wk Range
$3.91 - $15.25
Watch "CEO of Inseego Dan Mondor Talks Company's Rise In 2020", an archived episode of The Watch List originally aired 08/26/2020 on the TD Ameritrade Network.
https://tdameritradenetwork.com/iframe/index.html?videoId=rB4AoXQqF_qBdCvjB4UAkA
Good updates all, thanks.
Sure there are a lot of bio`s trading in a range lately. Seems they`er out of favor of late, so pick your best ones like $RDHL, that have good trials and some form of cushion that can stem selloffs and average down if you can. That`s what i`ve been doing, as we know the market will rotate to biotech's.
Hurricane Laura poses biggest threat to U.S. oil in 15 years
(Aug 25, 2020 01:20PM ET)
By Erwin Seba
HOUSTON (Reuters) - The U.S. energy industry began preparing for a major hurricane strike by Tuesday, cutting crude production at a rate approaching the level of 2005's Hurricane Katrina and halting oil refining at plants along the Texas/Louisiana coast.
The storm will rapidly gain strength and become a major hurricane with sustained, 115 mile per hour (185 kph) winds when it strikes the coast by early Thursday, according to the National Hurricane Center.
The intensification will bring at least a 10-foot (3-meter) storm surge to the upper Texas coast and could produce a devastating category 4 hurricane, said Chris Kerr, a meteorologist at agriculture, energy and weather data provider DTN.
On Monday, the storm had shut 1.5 million barrels per day (bpd) of crude oil output, 82% of Gulf of Mexico's offshore production, near the 90% outage that Katrina brought 15 years ago.
Refiners halted facilities that process at least 1.8 million bpd of oil processing, 10% of the U.S. total capacity, according to Reuters tallies. Gasoline prices rose Tuesday on the shutdowns and have jumped 10.3% since Friday.
"There will be a significant storm surge from Galveston (Texas) to the Sabine River," an area encompassing some of the region's largest refineries, said DTN's Kerr. "There are ideal conditions in central and west Gulf for rapid intensification."
Officials in Port Arthur, an energy city of 54,000 people, and similar-sized Galveston, Texas, each ordered mandatory evacuations as Laura began its march up the central Gulf of Mexico.
The storm will make landfall in an area that accounts for more than 45% of total U.S. petroleum refining capacity and 17% of oil production, according to the Energy Information Administration.
Cheniere Energy (NYSE:LNG) Inc, the largest U.S. exporter of liquefied natural gas, evacuated staff and suspended operations at its Sabine Pass LNG export terminal on the Texas/Louisiana border.
Motiva Enterprises, Total SA (NYSE:TOT) and Valero Energy (NYSE:VLO) began cutting operations at their Port Arthur, Texas, refineries, according to people familiar with the matter. The three combined process more than 900,000 bpd of oil.
Total and Motiva confirmed the shutdowns of their refineries. Valero declined to comment.
Exxon Mobil Corp (NYSE:XOM) began shutting production at its large Beaumont, Texas, refinery and reduced output at its Baytown, Texas, plant ahead of a possible shutdown, people familiar with the matter said.
An Exxon spokesman did not have immediate comment. If its Baytown plant fully halts processing, total shutdowns would hit more than 2.3 million bpd.
https://www.investing.com/news/commodities-news/hurricane-laura-poses-biggest-threat-to-us-oil-in-15-years-2276101
Appreciate your updates as this company gets no U.S. news feeds. TD Ameritrade, Seeking Alpha zero updates on a U.S. listed stock.
To bad this company is so obscure that few know it even exists. Down over 27% the past 3 months with only a slight bump before earnings and heading towards a Nasdaq warning of delisting too as it trades below $1.
Holding my shares until Nasdaq warning if it comes then i`ll decide if I will continue holding. This has been dead money play for a long while. GLTA
Solid bounce off the 200 SMA average.
Volume(Heavy Day)
1,133,501
August 19, 2020 1:11pm ET
Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks
Maya Sasson
August 17, 2020, 12:30 PM
https://www.tipranks.com/news/article/billionaire-steven-cohen-pulls-the-trigger-on-these-3-penny-stocks/
First up we have Otonomy, which is focused on providing new treatment options for patients living with the debilitating impacts of disorders of the ear. Its strong pipeline and $3.51 share price have scored it substantial praise from the pros on Wall Street.
This is the stance taken by Cohen. Increasing its stake in the company by a whopping 388%, Point72 snapped up 774,259 shares in Q2. With the total size of the holding now landing at 974,259 shares, the position is valued at $3,527,000.
5-star analyst Charles Duncan, of Cantor, also counts himself as a fan. The analyst believes there are numerous clinical catalysts on the horizon that should be significant value drivers for the stock if successful.
“In addition to the positive topline data for OTO-313 in tinnitus that was PR’d in early 3Q20, we anticipate additional data reads over the next ~9 months. These potential value creation milestones include topline data from the pivotal P3 OTIVIDEX study, which we believe may lead to an NDA filing in 2021E, as well as data from the signal-seeking P1/2 study of OTO-413 in hearing loss(4Q20E). We believe these readouts could re-affirm Otonomy’s leadership position in the emerging field of high unmet need neuro-otology, as well as reinvigorate investor interest,” Duncan opined.
That said, Duncan remains focused on the Phase 3 study of OTIVIDEX in Ménière’s disease, the enrollment for which should wrap up in Q3 2020. The analyst is “encouraged that despite the challenges to trial conduct during this time, the company has noted that patient compliance remains high for reporting vertigo symptoms and that the integrity of efficacy data being collected via a daily telephone diary is intact.”
To this end, the top analyst rates OTIC an Overweight (i.e. Buy) along with an $11 price target. This target implies shares could climb 212% higher in the next twelve months. (To watch Duncan’s track record, click here)
It’s not often that the analysts all agree on a stock, so when it does happen, take note. OTIC’s Strong Buy consensus rating is based on a unanimous 5 Buys. The stock’s $9.40 average price target suggests a 167% upside from current levels. (See Otonomy stock analysis on TipRanks)
Inseego files to sell 89,928 shares of common stock
REGISTRATION STATEMENT
https://www.sec.gov/Archives/edgar/data/1022652/000168316820002755/inseego_s3asr.htm
Slack shares are trading higher. Strength potentially related to increased usage of virtual communications platforms as businesses continue to adopt a work-from-home model.
Aug 3, 2020 2:30p ETBenzinga Stock Analysis
midastouch017
Appreciate your posting the updates.
Pfizer Q2 2020 Earnings Preview
Jul. 27, 2020 12:53 PM ET|About: Pfizer Inc. (PFE)|By: Mohit Manghnani, SA News Editor
Pfizer (NYSE:PFE) is scheduled to announce Q2 earnings results on Tuesday, July 28th, before market open.
The consensus EPS Estimate is $0.66 (-17.5% Y/Y) and the consensus Revenue Estimate is $11.55B (-12.9% Y/Y).
Adjusted R&D expenses is seen at $2.02B.
Over the last 2 years, PFE has beaten EPS estimates 88% of the time and has beaten revenue estimates 63% of the time.
Over the last 3 months, EPS estimates have seen 0 upward revisions and 8 downward. Revenue estimates have seen 1 upward revision and 6 downward.
https://seekingalpha.com/news/3595317-pfizer-q2-2020-earnings-preview
This morning The Street.com named MYOV as Stock of the Week. Do not have subscription though with more details.
Slack (NYSE:WORK) Shares Purchased by Raymond James Financial Services Advisors Inc.
Posted by Shane Hupp on Jul 23rd, 2020
Raymond James Financial Services Advisors Inc. boosted its stake in Slack (NYSE:WORK) by 47.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 185,133 shares of the company’s stock after purchasing an additional 59,502 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Slack were worth $5,756,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of WORK. Morgan Stanley increased its holdings in Slack by 61.1% in the 1st quarter. Morgan Stanley now owns 57,901,739 shares of the company’s stock valued at $1,554,083,000 after purchasing an additional 21,959,800 shares during the last quarter. Alliancebernstein L.P. increased its holdings in Slack by 376.7% in the 4th quarter. Alliancebernstein L.P. now owns 6,620,586 shares of the company’s stock valued at $148,831,000 after purchasing an additional 5,231,846 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Slack by 16.9% in the first quarter. Wellington Management Group LLP now owns 31,474,971 shares of the company’s stock worth $844,789,000 after acquiring an additional 4,556,329 shares in the last quarter. Nuveen Asset Management LLC acquired a new position in shares of Slack in the fourth quarter worth $58,993,000. Finally, Yale University acquired a new position in shares of Slack in the first quarter worth $45,103,000. Hedge funds and other institutional investors own 51.75% of the company’s stock.
Several research firms have commented on WORK. Credit Suisse Group boosted their price target on shares of Slack from $26.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, June 5th. William Blair restated a “buy” rating on shares of Slack in a research note on Friday, March 27th. Oppenheimer restated a “hold” rating on shares of Slack in a research note on Friday, June 5th. Stephens boosted their price target on shares of Slack from $32.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, May 29th. Finally, Goldman Sachs Group downgraded shares of Slack from a “neutral” rating to a “sell” rating and set a $30.00 target price for the company. in a research note on Friday, June 19th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company. Slack presently has an average rating of “Buy” and an average target price of $34.17.
In related news, CTO Cal Henderson sold 1,500 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $33.02, for a total transaction of $49,530.00. Following the completion of the transaction, the chief technology officer now directly owns 43,560 shares of the company’s stock, valued at $1,438,351.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Robert Frati sold 33,623 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $25.93, for a total transaction of $871,844.39. Following the transaction, the senior vice president now directly owns 386,822 shares of the company’s stock, valued at $10,030,294.46. The disclosure for this sale can be found here. Insiders sold 2,304,610 shares of company stock valued at $76,115,631 over the last ninety days. Corporate insiders own 26.82% of the company’s stock.
Shares of WORK opened at $30.94 on Thursday. The firm has a fifty day moving average price of $32.65 and a 200 day moving average price of $27.60. Slack has a 1-year low of $15.10 and a 1-year high of $40.07. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.32 and a quick ratio of 3.32. The stock has a market cap of $17.23 billion and a PE ratio of -21.64.
Slack (NYSE:WORK) last announced its earnings results on Thursday, June 4th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12. Slack had a negative net margin of 87.91% and a negative return on equity of 79.21%. The business had revenue of $201.65 million during the quarter, compared to analysts’ expectations of $188.12 million. Slack’s revenue was up 49.6% compared to the same quarter last year. As a group, equities analysts expect that Slack will post -0.58 EPS for the current fiscal year.
About Slack
Slack Technologies, Inc operates Slack, a business technology software platform in the United States and internationally. Its platform brings together people, applications, and data, as well as sells its offering under a software-as-a-service model. The company was formerly known as Tiny Speck, Inc and changed its name to Slack Technologies, Inc in 2014.
https://www.tickerreport.com/banking-finance/5993509/slack-nysework-shares-purchased-by-raymond-james-financial-services-advisors-inc.html
Jul 23, 2020 9:17 AM
ARAV Aravive price target raised to $26 from $15 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm's price target on Aravive to $26 from $15 and keeps a Buy rating on the shares after the company announced the completion of its Phase 1b trial testing AVB-500 in patients with platinum-resistant ovarian cancer. As expected, these data confirmed prior observations of safety and efficacy and provided key information for the design of the upcoming Phase 2/3 trial, Pantginis tells investors in a research note.
July 23, 2020
Northland Securities analyst Tim Chiang maintained a Buy rating on Kala Pharmaceuticals (KALA) today and set a price target of $17.00. The company’s shares closed last Wednesday at $10.24.
https://www.smarteranalyst.com/new-blurbs/kala-pharmaceuticals-kala-gets-a-buy-rating-from-northland-securities/
Concerns about competitive pressure from Microsoft Teams are "overblown" for Slack (NYSE:WORK), says FBN Securities analyst Shebly Seyrafi.
FBN starts Slack at Outperform and a Street-high $45 price target.
Seyrafi says the market has room for both collaboration offerings to "thrive" and notes Slack's "healthy" growth in paid customers and ARPU last quarter.
The analyst sees "good upside" in Slack shares due to the revenue multiple, and the fact that Slack hasn't rallied as much as other remote work-related stocks.
Slack shares are up 1.1% pre-market to $31.94. WORK shares are up 41% YTD compared to Zoom Video's 265% growth.
https://seekingalpha.com/news/3592233-slack-gets-street-high-target-on-overblown-teams-competition
Pfizer CEO Albert Bourla Raises Expectations That the Pharmaceutical Giant Can Deliver a COVID-19 Vaccine by Fall
https://time.com/5864690/pfizer-vaccine-coronavirus/
Pfizer's Progress
https://seekingalpha.com/article/4358545-pfizers-progress
Gap filled:
A lot of upper gap to fill/ enjoy the ride.....
In my 32 years investing a gap will always fill before running up/down to the next level. I`ve a GTC buy at $17.50 but if there is a B/O or something that makes it run, i`m good with that as it`s products are going to be great for the market. GL
7:44 am ET June 23, 2020
Cellectar Biosciences started at buy with $3 stock price target at Maxim Group
Maxim analyst Jason McCarthy initiated coverage of Cellectar Biosciences with a Buy rating and $3 price target. The analyst says the data in the company's development of phospholipid drug conjugates to target cancer's "addiction" to phospholipids have been "compelling". McCarthy further notes additional catalysts expected in the second half of 2020 and in 2021, with "updates on a pediatric study in solid tumors and r/r blood cancers", adding that Cellectar should also have cash runway well into 2021
This mornings at the open
Took profits and will re-enter when gap is filled.
Myovant conference call tomorrow on Phase 3 relugolix data in endometriosis
Jun. 22, 2020 4:10 PM ET|About: Myovant Sciences Ltd. (MYOV)
Myovant Sciences (NYSE:MYOV) will host a webcast and conference call tomorrow, June 23, at 8:30 am ET to discuss results from a Phase 3 clinical trial, SPIRIT 1, evaluating once-daily relugolix combo therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis.
Shares up 2% after hours.
The webcast and conference call to discuss the data will be held on Tuesday, June 23, 2020 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. To participate in the live conference call, please dial 1-800-532-3746 for domestic callers and +1-470-495-9166 for international callers. A live webcast of the conference call will also be available on the investor relations page of Myovant's website at investors.myovant.com and will remain archived on Myovant's website for at least 30 days.
News just keeps coming in:
FDA accepts Myovant application for relugolix for prostate cancer
The FDA accepts for review Myovant Sciences' (MYOV +2.8%) marketing application for relugolix for the treatment of advanced prostate cancer. The agency's action date is December 20.
On June 1, it filed a U.S. application for a relugolix combo pill for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.
https://seekingalpha.com/news/3584919-fda-accepts-myovant-application-for-relugolix-for-prostate-cancer?v=1592837908
Sure dose not look as this will be the case. Don`t understand the weak stock price except for the spin off concerns there has been a lot of positive news. Have to remember there are a lot of shares outstanding also.
Pfizer launches four late-stage studies on vaccine candidates
Jun. 22, 2020 8:42 AM ET|About: Pfizer Inc. (PFE)|
Pfizer (NYSE:PFE) has initiated Phase 3 clinical trials on vaccine candidates for preventing pneumonia, RSV and meningitis.
20-valent pneumococcal vaccine (20vPnC): Two studies, NCT04382326 and NCT04379713, will assess a four-dose series in healthy infants. The former is aimed at determining immunologic non-inferiority to Prevnar 13.
RSV vaccine (RSVpreF): Study NCT04424316 is assessing the vaccine in infants born to immunized women.
Pentavalent meningococcal vaccine (MenABCWY): Study NCT04440163 is assessing the vaccine in adolescents and young adults aimed at determining non-inferiority to licensed vaccines.
https://seekingalpha.com/news/3584877-pfizer-launches-four-late-stage-studies-on-vaccine-candidates
Parsley Energy Inc (NYSE:PE) Position Lessened by Aviva PLC
https://www.tickerreport.com/banking-finance/5793124/parsley-energy-inc-nysepe-position-lessened-by-aviva-plc.html
Oil - Brent Backwardation Comes Sooner Than Expected
https://seekingalpha.com/article/4354735-oil-brent-backwardation-comes-sooner-expected
A few days old but it`s a reminder what $PFE is doing too:
Fauci just criticized Moderna for touting preliminary data on its coronavirus vaccine, but said the results look 'very promising'
"The Pfizer one is very similar to Moderna's," Fauci said, referring to Pfizer's work with BioNTech on four variations of a coronavirus vaccine. "It's an mRNA vaccine. I'm sure that Pfizer is going to get results that are as good as the Moderna vaccine. There's no reason to believe one is going to be any different than the other."
https://www.businessinsider.com/fauci-criticize-moderna-early-preliminary-data-coronavirus-vaccine-promising-2020-6